CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
Go back to CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)| CARLISLE COMPANIES, Inc. (NYSE: CSL) | Delayed: 317.85 +3.15 (1.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $314.70 | 52 Week High | $114.49 | |||
| Open | $321.80 | 52 Week Low | $75.17 | |||
| Day High | $321.80 | P/E | 88.05 | |||
| Day Low | $310.39 | EPS | $3.61 | |||
| Volume | 524,017 | |||||
| (AMEX: CSLLY) | Delayed: 31.91 +0.81 (2.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.10 | 52 Week High | $45.60 | |||
| Open | $31.80 | 52 Week Low | $33.39 | |||
| Day High | $31.96 | P/E | N/A | |||
| Day Low | $31.50 | EPS | $0.00 | |||
| Volume | 46,032 | |||||
